GLP-1 Drugs List: Every FDA-Approved GLP-1 Medication in 2026

This GLP-1 drugs list covers every FDA-approved GLP-1 drug sold in the US as of September 2026. Today's products come from seven active ingredients: semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide, orforglipron, and lixisenatide. You know them as Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Trulicity, Victoza, Saxenda, and Foundayo, plus generic liraglutide, generic exenatide, and two insulin combinations.

Much of this GLP-1 medications list is new. The Wegovy pill launched in January 2026, the FDA approved Foundayo on April 1, 2026, and Ozempic tablets reached US pharmacies on May 4, 2026. Because these drugs act on the same receptor, their labels share many warnings. For one detailed example of the side effects, see our article on Zepbound side effects.

On this page you will find:

• One master table with every brand, its maker, form, schedule, and approved uses
• Which GLP-1 medications are approved for weight loss and which for type 2 diabetes
• The four GLP-1 pills and how each one is taken
• Generics, discontinued drugs, and the pipeline drugs that are not approved yet
• The safety warnings the whole class shares

Table of Contents

• The complete GLP-1 medications list (2026)
• What are GLP-1 medications?
• GLP-1 medications for weight loss
• GLP-1 medications for type 2 diabetes
• GLP-1 pills vs injections
• Each GLP-1 drug at a glance
• How to choose between GLP-1 medications
• Eating well on any GLP-1 medication
• Generic and compounded GLP-1 medications
• Discontinued GLP-1 medications
• GLP-1 drugs in development (not FDA-approved)
• Safety warnings shared by GLP-1 medications
• Frequently asked questions

The Complete GLP-1 Medications List (2026)

The complete GLP-1 medications list for the US has 15 current products from seven active ingredients. The brands come from Novo Nordisk, Eli Lilly, and Sanofi, and the generics from several other makers. Each row below comes from the product's own FDA Prescribing Information.

Sources: the FDA Prescribing Information for each product (revision dates in References) and Drugs@FDA, as of September 2026. CV means cardiovascular.

Two notes on the table. Adlyxin (lixisenatide alone) is still listed as an approved prescription product in Drugs@FDA, but we could not confirm from a primary source whether it is sold in the US today, so it is not in the table. The weight-loss brands are approved "in combination with a reduced-calorie diet and increased physical activity," the wording in their labels.

What Are GLP-1 Medications?

GLP-1 medications are prescription drugs that act like GLP-1, a hormone your gut releases after meals. They activate the GLP-1 receptor, which helps lower blood sugar and reduces appetite. Many people on these medicines also describe quieter "food noise"; see what food noise is and what studies show. Every drug on this GLP-1 drugs list is prescription only. Supplements sold as "GLP-1 boosters" are not on this list; see GLP-1 supplements for what they contain.

The class is no longer one type of molecule. Three differences matter:

• Classic GLP-1 receptor agonists. Semaglutide, liraglutide, dulaglutide, exenatide, and lixisenatide act on the GLP-1 receptor.
• Dual agonist. Tirzepatide (Mounjaro, Zepbound) is "a GIP receptor and GLP-1 receptor agonist," according to the Zepbound label, so it acts on a second gut hormone receptor too.
• Small-molecule pill. Orforglipron (Foundayo) activates the GLP-1 receptor but is not a peptide, based on the chemistry section of its label. Its label allows it with or without food, unlike the semaglutide tablets.

You inject most of these drugs under the skin once a week or once a day. Four are tablets, covered in the pills section below.

GLP-1 Medications for Weight Loss

Six products on the GLP-1 drugs list are FDA-approved for weight loss: Wegovy injection (including Wegovy HD), the Wegovy pill, Zepbound, Foundayo, Saxenda, and generic liraglutide that references Saxenda. The FDA has not approved Ozempic, Mounjaro, or the other diabetes brands for weight loss, even when they contain the same molecule.

The table shows the headline result from each label's main weight-loss trial. These trials had different people, lengths, and placebo results, so the numbers are not head-to-head and cannot rank the drugs.

Sources: section 14 of the Zepbound, Wegovy, Foundayo, and Saxenda Prescribing Information. Doses shown are the highest trial doses, not a dosing guide. Foundayo trials used an investigational formulation; the label shows results as the equivalent Foundayo dose.

Few trials have compared these drugs directly. In the head-to-head SURMOUNT-5, 751 adults with obesity and without diabetes lost 20.2% of body weight on tirzepatide vs 13.7% on semaglutide after 72 weeks. Eli Lilly, which makes tirzepatide, funded the open-label trial. For the brand-by-brand breakdown, read Wegovy vs Zepbound. In the open-label STEP 8 trial, semaglutide 2.4 mg led to more weight loss than liraglutide 3 mg: 15.8% vs 6.4% at 68 weeks; Novo Nordisk makes both drugs and funded the trial. Our page on Saxenda vs Wegovy covers that trial and both labels side by side.

Some weight-loss brands carry extra approved uses:

• Wegovy injection and pill: lower risk of heart attack, stroke, and cardiovascular death in adults with heart disease and obesity or overweight.
• Wegovy injection: noncirrhotic MASH (fatty liver disease) with moderate to advanced fibrosis, approved on August 15, 2025 under accelerated approval.
• Zepbound: moderate to severe obstructive sleep apnea in adults with obesity, approved on December 20, 2024.

GLP-1 Medications for Type 2 Diabetes

Ten products on the GLP-1 drugs list treat type 2 diabetes: Ozempic injection, Ozempic tablets, Rybelsus, Mounjaro, Trulicity, Victoza, generic liraglutide, generic exenatide, Xultophy, and Soliqua. All of them lower blood sugar, and five brands also have an approved heart benefit.

Sources: section 1 of each Prescribing Information; approval dates from Drugs@FDA supplements.

The "heart benefit" means a lower risk of major cardiovascular events: cardiovascular death, nonfatal heart attack, or nonfatal stroke. Xultophy and Soliqua combine a GLP-1 with a long-acting insulin in one daily pen.

GLP-1 Pills vs Injections

Four entries on the GLP-1 drugs list are pills: the Wegovy pill, Foundayo, Ozempic tablets, and Rybelsus. Every other GLP-1 medication is an injection under the skin, given once a week (semaglutide, tirzepatide, dulaglutide) or once or twice a day (liraglutide, exenatide, the insulin combinations). No GLP-1 medicine is FDA-approved as a skin patch; read do GLP-1 patches work for what the products sold online contain.

The pills are not taken the same way. The semaglutide tablets need an empty stomach, while Foundayo does not. For the full Wegovy pill routine, see how to take the Wegovy pill. To compare the tablet with the weekly shot, see Wegovy pill vs injection.

Sources: section 2 of the Wegovy, Rybelsus and Ozempic tablets, and Foundayo Prescribing Information.

Rybelsus became the first oral GLP-1 when the FDA approved it in 2019. Novo Nordisk calls the Wegovy pill, approved on December 22, 2025, the first oral GLP-1 medicine for obesity in the US. Ozempic tablets reached US pharmacies on May 4, 2026. Novo Nordisk says the US product has been renamed and asks Rybelsus users to talk to their prescriber about switching. The two are "not substitutable on a mg-to-mg basis," the label warns, so ask your prescriber how to switch.

Each GLP-1 Drug at a Glance

Seven active ingredients are behind today's GLP-1 brands: semaglutide has five products, tirzepatide two, liraglutide three plus generics, and dulaglutide, orforglipron, exenatide, and lixisenatide one each. Each profile below is short; dose schedules and brand comparisons belong on their own pages.

Semaglutide: Ozempic, Wegovy, Rybelsus

Semaglutide has the most products on this list: five, all from Novo Nordisk. Ozempic (approved in 2017), Ozempic tablets, and Rybelsus (2019) treat type 2 diabetes. Wegovy (2021) and the Wegovy pill treat weight and lower heart risk. The FDA approved Wegovy HD, a higher 7.2 mg weekly dose, on March 19, 2026, and it launched on April 7, 2026. The diabetes and weight brands are separate products with separate approvals, even with the same molecule.

Tirzepatide: Mounjaro and Zepbound

Tirzepatide is Eli Lilly's dual GIP and GLP-1 receptor agonist, sold as Mounjaro (approved May 13, 2022) for type 2 diabetes and Zepbound (approved November 8, 2023) for weight and sleep apnea. See our Zepbound vs Mounjaro comparison for how the two brands differ. Both come in four presentations: single-dose pen, single-dose vial, KwikPen, and multi-dose vial. Our Zepbound KwikPen guide explains the multi-dose pen. In 2025 and 2026 Mounjaro added children 10 and older and a heart indication. For label dose steps, see our tirzepatide dosage chart. For practical tips, see where to inject Zepbound.

Liraglutide: Victoza, Saxenda, and generics

Liraglutide is a once-daily injection. Novo Nordisk sells it as Victoza (2010) for type 2 diabetes and Saxenda (2014) for weight management. On December 23, 2024, the FDA approved the first generic of Victoza, which it called the first generic of a once-daily GLP-1. A Teva generic of Saxenda followed in August 2025, which Teva describes as the first generic GLP-1 for weight loss. Novo Nordisk has announced that it will discontinue the Saxenda brand, with last shipments to wholesalers in late January 2027.

Dulaglutide: Trulicity

Dulaglutide is Eli Lilly's once-weekly injection, sold as Trulicity since 2014. It comes in single-dose pens and treats type 2 diabetes in adults and children 10 and older. Its label also includes a lower risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes and heart disease or multiple risk factors.

Orforglipron: Foundayo

Orforglipron is Eli Lilly's once-daily GLP-1 tablet, sold as Foundayo since its approval on April 1, 2026. Its only approved use is weight loss and maintenance in adults. Lilly describes it as the only oral GLP-1 taken without food or water restrictions. Lilly reported a US filing for type 2 diabetes in its August 5, 2026 results; the FDA has not approved that use yet. Lilly's self-pay price for each dose is in our Foundayo cost guide. To see how it compares with the weekly shot, read Foundayo vs Zepbound.

Exenatide: generic only

Exenatide is the oldest ingredient on this list: the FDA approved it as Byetta in 2005. Its brand versions, Byetta, Bydureon, and Bydureon BCise, have since left the market (see below). On November 19, 2024, the FDA approved Amneal's generic exenatide, the first generic in the GLP-1 class. It is a twice-daily pen for type 2 diabetes in adults.

Combination products: Xultophy and Soliqua

Two once-daily pens pair a GLP-1 with a basal insulin, both approved on November 21, 2016. Xultophy 100/3.6 (Novo Nordisk) combines insulin degludec and liraglutide. Soliqua 100/33 (Sanofi) combines insulin glargine and lixisenatide. Both treat type 2 diabetes in adults only.

How to Choose Between GLP-1 Medications

Choosing between GLP-1 medications starts with what the drug is approved for, then your route, schedule, other conditions, and coverage. It is a decision to make with your prescriber, and no label ranks one brand above another.

Questions to bring to your appointment:

1. What is the goal? Weight management, type 2 diabetes, sleep apnea, heart risk, or liver disease each have different approved options (see the tables above).
2. Shot or pill? Weekly shots, daily shots, a fasting pill, or a pill with no food rules.
3. What other conditions do I have? Heart disease, chronic kidney disease, or MASH can point to a brand with that indication.
4. Do any warnings apply to me? A personal or family history of medullary thyroid cancer or MEN 2 rules most of these drugs out.
5. What does my plan cover? Ask whether your plan covers the brand approved for your diagnosis.
6. What if I need to switch? Switching between brands, or from Rybelsus to Ozempic tablets, is a prescriber decision with its own dose plan.

Head-to-head trial results are covered in our brand comparisons. Even when one drug led to more weight loss in a trial, the best drug for you also depends on how well you tolerate it and whether you can stay on it.

Eating Well on Any GLP-1 Medication

Eating well matters on every GLP-1 medication, because each weight-management label approves the drug "in combination with a reduced-calorie diet and increased physical activity." The Zepbound, Wegovy, Foundayo, and Saxenda labels all use that wording.

A smaller appetite makes every meal count. A 2025 joint advisory from four nutrition and obesity societies notes that protein targets of 1.2 to 1.6 grams per kilogram of body weight per day have been proposed during active weight loss. It adds that the right body weight for that math is unsettled and that strength training is also needed to protect muscle.

Simple habits that help on any GLP-1 drug (these are general tips, not label instructions):

• Protein first. Start each meal with the protein part, before appetite fades.
• Smaller, planned meals. Plan portions ahead so a low appetite does not turn into skipped meals.
• Fluids through the day. Sip water regularly, especially if you have nausea or diarrhea.
• Strength training. Pair protein with resistance exercise at least 3 times a week, as the 2025 advisory suggests.

If you want a high-protein meal plan with recipes sized for a smaller appetite, see our GLP-1 meal plan and protein guide. The same approach works whether you take a weekly shot or a daily pill.

Generic and Compounded GLP-1 Medications

Two generic GLP-1 medications are FDA-approved: generic liraglutide and generic exenatide. No generic semaglutide or tirzepatide can be sold in the US yet. Drugs@FDA shows one semaglutide generic application (Apotex) with tentative approval only, which means Apotex cannot sell it yet.

Generic liraglutide now comes from several companies, including Hikma, Teva, Lupin, Biocon, and Sandoz. Versions that reference Victoza treat type 2 diabetes, and versions that reference Saxenda treat weight.

Compounded GLP-1 drugs are a different category. The FDA states that compounded drugs are not FDA approved and that it does not review them for safety, effectiveness, or quality before they are marketed. That is why none appear in this GLP-1 medications list. For the legal status and risks, read our page on compounded tirzepatide. Berberine patches sold online as a "natural GLP-1" are not GLP-1 medicines either; see berberine patches: do they work?.

Discontinued GLP-1 Medications

Four GLP-1 medications have left the US market: Byetta, Bydureon BCise, Bydureon, and Tanzeum. The ingredient behind Byetta, exenatide, is still available as a generic.

Sources: FDA pediatric pharmacovigilance review of Bydureon BCise, Bydureon, and Byetta (April 14, 2025) and Drugs@FDA marketing status.

If you still have one of these products at home, do not start or restart it on your own; ask your prescriber about a current option.

GLP-1 Drugs in Development (Not FDA-Approved)

None of the GLP-1 drugs in development belongs on the GLP-1 drugs list yet, because the FDA has not approved them. The table shows where the best-known candidates stand as of September 2026, based on company filings and ClinicalTrials.gov.

Sources: Novo Nordisk (December 18, 2025 release and H1 2026 report), Eli Lilly Q2 2026 results, ClinicalTrials.gov.

Products sold online under these names are not FDA-approved medicines. The FDA says retatrutide and cagrilintide cannot be used in compounding under federal law. It has also warned companies that sold unapproved retatrutide, survodutide, and other GLP-1 drugs labeled "for research purposes" or "not for human consumption." Our explainer on retatrutide side effects covers the published trial data. For how its trial results compare with tirzepatide's, read retatrutide vs tirzepatide.

Safety Warnings Shared by GLP-1 Medications

Most GLP-1 medications carry a boxed warning about thyroid C-cell tumors, based on rodent studies of GLP-1 drugs. People with a personal or family history of medullary thyroid carcinoma (MTC), or with MEN 2, must not use them. The Zepbound Medication Guide, for example, says to tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath.

Foundayo carries the same boxed warning and the same MTC and MEN 2 contraindication. Its label explains that orforglipron is not active in rats or mice, so rodent studies could not show this risk, and whether it matters in people is unknown. The Soliqua and generic exenatide labels carry no boxed warning.

Other warnings repeat across the class labels:

• Serious allergic reactions. Swelling of the face, lips, tongue, or throat, or trouble breathing or swallowing: stop the medicine and get medical help right away.
• Pancreatitis. For Zepbound, for example, stop the medicine and call your healthcare provider right away if you have severe stomach pain that will not go away, with or without nausea or vomiting; the pain may spread to your back.
• Gallbladder problems, including gallstones. For Zepbound, tell your healthcare provider right away about upper stomach pain, fever, yellow skin or eyes, or clay-colored stools.
• Low blood sugar when combined with insulin or a sulfonylurea.
• Kidney injury from dehydration after vomiting or diarrhea. Drink fluids, and tell your healthcare provider right away if nausea, vomiting, or diarrhea does not go away.
• Severe stomach problems. Not recommended in severe gastroparesis.
• Diabetic eye complications in people with type 2 diabetes.
• Aspiration during anesthesia or deep sedation. Tell your care team you take a GLP-1 before any procedure.

Three more label rules come up often, though not on every label:

• Combining GLP-1 drugs. The Zepbound, Wegovy, Saxenda, Foundayo, Xultophy, and Soliqua labels say use with another GLP-1 receptor agonist is not recommended. Any change of drug is a prescriber decision.
• Pregnancy. The Zepbound and Foundayo labels say to stop the drug when pregnancy is recognized, and so does the Wegovy label for weight or heart risk use. The Ozempic and Wegovy labels also advise stopping at least 2 months before a planned pregnancy.
• Birth control pills. The Zepbound and Mounjaro labels advise switching to a non-oral method or adding a barrier method for 4 weeks after starting and after each dose increase. The Foundayo label says 30 days.

For a full example of how often side effects happen on one drug, see our Zepbound side effects guide.

Key Takeaways

• Fifteen current products. This GLP-1 drugs list counts 15 FDA-approved products from seven ingredients.
• Weight vs diabetes. Six products are approved for weight loss and ten for type 2 diabetes; generic liraglutide appears in both groups.
• Four pills. The Wegovy pill and Foundayo treat weight; Ozempic tablets and Rybelsus treat diabetes.
• Generics exist. Generic liraglutide and exenatide are approved; generic semaglutide and tirzepatide are not sold yet.
• Pipeline is not approved. CagriSema, retatrutide, and others are still under review or in trials.

Keep this GLP-1 medications list handy as a starting point, and choose your medicine with your prescriber based on your diagnosis, your health history, and your coverage.

Frequently Asked Questions

How many GLP-1 medications are there?

As of September 2026, our list counts 15 FDA-approved GLP-1 products on the US market, counting generic liraglutide as one entry. They come from seven active ingredients: semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide, orforglipron, and lixisenatide (inside Soliqua).

What are the most popular GLP-1 medications?

The best-known brands are Ozempic and Wegovy (semaglutide) and Mounjaro and Zepbound (tirzepatide). We did not find an official public ranking by number of prescriptions, so we do not rank them.

Which GLP-1 medication works best for weight loss?

Few trials compare these drugs directly; in the head-to-head SURMOUNT-5 trial, tirzepatide led to more weight loss than semaglutide at 72 weeks. The right choice still depends on your health, how you tolerate the drug, and coverage, so decide with your prescriber.

Is there a GLP-1 pill for weight loss?

Yes, two. The FDA approved the Wegovy pill (semaglutide) on December 22, 2025, and Foundayo (orforglipron) on April 1, 2026. Ozempic tablets and Rybelsus are pills too, but they treat type 2 diabetes, not weight.

What is the cheapest GLP-1 medication?

There is no single cheapest GLP-1. What you pay depends on your insurance, your pharmacy, and whether you use a maker's self-pay program, and those prices change often. Generic liraglutide and generic exenatide are FDA-approved, but a generic is not always the lowest-cost option. Ask your pharmacist to compare the options your plan covers and their cash prices.

Who cannot take a GLP-1 medication?

Most GLP-1 labels say not to use the drug if you or a family member has had medullary thyroid carcinoma (MTC), if you have MEN 2, or if you have had a serious allergic reaction to the medicine. They are also not recommended in severe gastroparesis, and the Zepbound and Foundayo labels say to stop when pregnancy is recognized.

Is Mounjaro a GLP-1?

Yes. Mounjaro contains tirzepatide, which activates both the GIP and GLP-1 receptors. It treats type 2 diabetes, while Zepbound, the same molecule, treats weight and sleep apnea.

Is retatrutide FDA-approved?

No. Retatrutide is still in phase 3 trials, and Eli Lilly plans to apply for FDA approval in the first quarter of 2027. Products sold online as retatrutide are not FDA-approved.

Can you take two GLP-1 medications together?

Usually not. The Zepbound, Wegovy, Saxenda, Foundayo, Xultophy, and Soliqua labels say using them with another GLP-1 receptor agonist is not recommended. Not every GLP-1 label has that line, so ask your prescriber before combining or switching.

References

1. Ozempic (semaglutide) injection Prescribing Information, revised 05/2026: Novo Nordisk
2. Rybelsus and Ozempic (semaglutide) tablets Prescribing Information, revised 1/2026: Novo Nordisk
3. Wegovy (semaglutide) injection and tablets Prescribing Information, revised 06/2026: Novo Nordisk
4. Mounjaro (tirzepatide) Prescribing Information, revised 08/2026: Eli Lilly
5. Zepbound (tirzepatide) Prescribing Information, revised 08/2026: Eli Lilly
6. Trulicity (dulaglutide) Prescribing Information, revised 03/2026: Eli Lilly
7. Victoza (liraglutide) Prescribing Information, revised 10/2025: Novo Nordisk
8. Saxenda (liraglutide) Prescribing Information, revised 02/2026: Novo Nordisk
9. Foundayo (orforglipron) Prescribing Information, revised 07/2026: Eli Lilly
10. Xultophy 100/3.6 (insulin degludec and liraglutide) Prescribing Information, revised 10/2025: Novo Nordisk
11. Soliqua 100/33 (insulin glargine and lixisenatide) Prescribing Information, revised 03/2026: Sanofi
12. Exenatide injection (Amneal, ANDA 206697) label, effective 2026-05-27: openFDA
13. Drugs@FDA: FDA-approved drug products database: U.S. Food and Drug Administration
14. FDA approves first generic of once-daily GLP-1 injection to lower blood sugar in patients with type 2 diabetes, December 23, 2024: U.S. Food and Drug Administration
15. Teva announces FDA approval and launch of generic Saxenda (liraglutide injection), August 28, 2025: Teva
16. Pediatric postmarketing pharmacovigilance review: Bydureon BCise, Bydureon, and Byetta, April 14, 2025: U.S. Food and Drug Administration
17. FDA's concerns with unapproved GLP-1 drugs used for weight loss, content current as of 09/01/2026: U.S. Food and Drug Administration
18. FDA approves Novo Nordisk's Wegovy pill, December 22, 2025: Novo Nordisk
19. FDA approves Novo Nordisk's new Wegovy HD injection, March 2026: Novo Nordisk
20. Novo Nordisk's Ozempic pill soon to be available in the US, May 1, 2026: Novo Nordisk
21. Novo Nordisk financial report for the first six months of 2026 (Form 6-K), August 4, 2026: U.S. Securities and Exchange Commission
22. Novo Nordisk files for FDA approval of CagriSema, December 18, 2025: Novo Nordisk
23. Lilly reports second-quarter 2026 financial results (Form 8-K exhibit), August 5, 2026: U.S. Securities and Exchange Commission
24. Aronne LJ et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med, 2025
25. Rubino DM et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA, 2022;327(2):138-150
26. Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med, 2023
27. ClinicalTrials.gov registry: phase 3 studies of retatrutide, maridebart cafraglutide, and survodutide: U.S. National Library of Medicine
28. Nutritional priorities to support GLP-1 therapy for obesity: joint advisory from ACLM, ASN, OMA, and TOS, 2025

This page is for education only and is not medical advice. It summarizes FDA labels, FDA records, and published research and gives no personalized dosing advice. Talk to your prescriber about which medicine fits you and at what dose. Read our full medical disclaimer.